Navigation Links
New sickle cell anemia therapy advances to Phase II clinical trials
Date:6/12/2013

SAN DIEGO (June 12, 2013) Seeking to improve the lives of sickle cell anemia sufferers around the world, researchers from the La Jolla Institute for Allergy and Immunology, the Dana-Farber/Children's Hospital Cancer Center in Boston and the BloodCenter of Wisconsin in Milwaukee and others are preparing to launch Phase II of a clinical trial to investigate a potential new therapy for reducing the disorder's severest symptoms. Sickle cell anemia is a serious, painful and chronic illness that impedes blood flow and can lead to early death. More than 100,000 Americans and several million people worldwide suffer from this genetic disorder.

The phase II trial, funded by a $10.8 million grant from the National Institutes of Health, is testing an already existing drug called Lexiscan (regadenoson - Astellas Pharma US, Inc.), which is used for diagnosing heart disease. Researchers are exploring whether the drug's anti-inflammatory effects will significantly reduce the pain and blood flow disturbances of sickle cell anemia. A Phase I safety study was completed earlier this year. Recruitment is now under way for the trial's second phase to be conducted at treatment centers in eight major U.S. cities: Boston, Baltimore, Detroit, Chicago, Cincinnati, Milwaukee, Chapel Hill, and St. Louis.

"We are excited to begin the next phase of investigating Lexiscan's potential for reducing inflammation that contributes to the poor blood flow and serious complications of sickle cell disease," says La Jolla Institute scientist Joel Linden, Ph.D., a prominent researcher whose studies laid the groundwork for the trial. "Our phase I results were promising. Participants experienced no adverse reactions and our tests indicated that the drug significantly reduces inflammation. It is too early to tell whether this will translate into reduced pain and tissue damage. But we remain cautiously optimistic." The Phase I results were published as the cover article in th
'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial?
2. Potential gene therapy approach to sickle cell disease highlighted at ASH
3. Nature study reveals loss of essential blood cell gene leads to anemia
4. Why a hereditary anemia is caused by genetic mutation in mechanically sensitive ion channel
5. Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
6. Discovery may help prevent chemotherapy-induced anemia
7. Scientists identify potential drug target for treatment-resistant anemias
8. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
9. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
10. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
11. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... prevention is worth a pound of cure" can easily ... Because taking off extra weight is an almost insurmountable ... especially childhood, is crucial to realizing optimal long-term health. ... being breastfed might predispose a person to being lean, ...
... The putative skull of Saint Bridget (Birgitta) of Sweden ... is probably not authentic. A new study conducted at Uppsala ... Saint Bridget and her daughter Catherine (Katarina), is not from ... not from the time period when Bridget and Catherine lived. ...
... research of Dr. Doris Taylor was achieved recently when ... agreement with Miromatrix Medical Inc. Dr. Taylor,s research ... that it had created a beating animal heart in ... the promise of one day enabling the replacement of ...
Cached Biology News:Later introduction of baby foods related to lower risk of obesity later in life 2The putative skull of St. Bridget can be questioned 2U of Minnesota finalizes license agreement to form start-up company based on Doris Taylor research 2
(Date:2/26/2015)... 2015   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today reported 2014 ... other key objectives, and financial guidance.  Synageva,s management ... 4:30 p.m. EST to review the financial results ... in today,s call by telephone, please dial (877) ...
(Date:2/26/2015)... NJ (PRWEB) February 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... a trade secrets lawsuit against Genewiz Inc. in excess ... obtained and utilized GenScript’s trade secrets, and that it ... The court entered an order denying motions for judgment ...
(Date:2/26/2015)... IL (PRWEB) February 26, 2015 Already ... its gauging line by expanding its Length Gauge offerings ... ACANTO gauges. , Specifically, HEIDENHAIN’s pencil probe-style ... improved force specification. Two new 1Vpp, 12mm stroke ... lower force applications. One is a variant with a ...
(Date:2/26/2015)... 2015 Regis Technologies announced new ... oncology drug substances. , Regis Technologies is proud to ... Potent Compound Suite (PCS) for 2015. , Regis is ... cGMP facility in Morton Grove, Illinois. The PCS addition ... compounds up to about one kilogram per batch. ...
Breaking Biology Technology:Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Regis Extends cGMP Services to Oncology Market 2
... of Energy,s Lawrence Berkeley National Laboratory and the ... world,s first all-integrated sensor circuit based on nanowire ... different crystalline materials. Their method can be used ... , Nanostructures made with specific chemical, electronic, ...
... Revenues - a record $35.5 million vs. $24.7 million in Q2 2007 ... - an increase of 43.4%, Q2 2008 Diluted Net Income per Share - ... ... Q2 2007 Q2 2008 New Bookings of $49.0 million vs. $34.5 million in Q2 2007, ...
... Conference, August 3-8, CHICAGO, Aug. 4 Criminal ... to reduce the spread of the virus.,Instead, it increases ... burdening women and other vulnerable groups who,are unable to ... violence,according to a commentary in the August issue of ...
Cached Biology Technology:A first in integrated nanowire sensor circuitry 2A first in integrated nanowire sensor circuitry 3A first in integrated nanowire sensor circuitry 4eResearchTechnology Reports Second Quarter 2008 Results 2eResearchTechnology Reports Second Quarter 2008 Results 3eResearchTechnology Reports Second Quarter 2008 Results 4eResearchTechnology Reports Second Quarter 2008 Results 5eResearchTechnology Reports Second Quarter 2008 Results 6eResearchTechnology Reports Second Quarter 2008 Results 7eResearchTechnology Reports Second Quarter 2008 Results 8eResearchTechnology Reports Second Quarter 2008 Results 9JAMA Commentary Opposes Criminal Punishment for HIV Exposure/Transmission 2JAMA Commentary Opposes Criminal Punishment for HIV Exposure/Transmission 3
... orbital shaker stands both present ... ergonomic height, and help protect ... welded tubular steel, these heavy-duty ... the weight and minimize the ...
... The dotLab System brings together two ... and immobilized capture surfaces. This combination ... technique for the detection of molecular ... fluorescent labels. , Protein-specific capture molecules ...
... Escherichia coli RY 13 5'G AATTC3' 3'CTTAA G5' ... min or ethanol precipitation. Storage Conditions: 10mM Tris-HCl ... 0.15% Triton X-100, 0.01% BSA, 50% glycerol. Shipping ... -20C. Unit Definition: One unit is defined as ...
The HEPTEST assays provide a sensitive, simple, rapid, and convenient in vitro quantitation of heparin, low molecular weight heparins, and heparinoids in plasma and whole blood. Sample Type: wh...
Biology Products: